Date: <u>2023-0</u>	01-09Chen Wany			
Your Name:	Creat A			
Manuscript Title:	_Choline suppresses her	patocellular carcinom	a progression by attenuating AM	PK/mTOR-mediated
autophagy via ch	oline transporter SLC5A7	7 activation		
Manuscript num	ber (if known):HBSN-2	2- 476-R1		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
_		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2023-01-09
Your Name: <u>Thas your lin</u>
مر Manuscript Title: <u>Choline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediated</u>
autophagy via choline transporter SLC5A7 activation
Manuscript number (if known): <u>HBSN-22- 476-R1</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>20</u>	23-01-09	
Your Name:	Wenge (Yuang	
Manuscript T	itle:_Choline suppresses hepatocellula	carcinoma progression by attenuating AMPK/mTOR-mediated
autophagy via	a choline transporter SLC5A7 activation	
Manuscript n	umber (if known):HBSN-22- 476-R1_	-

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2023-01-09 Zhr. Jun Yang
Your Name:
Manuscript Title: <u>Choline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediated</u>
autophagy via choline transporter SLC5A7 activation
Manuscript number (if known):HBSN-22- 476-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
_		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment,	None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-01-09 Diu-ye Lan Your Name:

Manuscript Title:<u>Choline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediated</u> autophagy via choline transporter SLC5A7 activation Manuscript number (if known):<u>HBSN-22- 476-R1</u>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert	None
•	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2	<u>023-01-09</u>		-	
Your Name		Ai-ping	rang	
Manuscript	Title: Choline cupp		onatocol	 Iular carcinoma progression by attenuating AMPK/mTOR-mediated
wanuscript	nue. <u>cnoine supp</u>	12325 11	epatocer	
autophagy	via choline transport	er SLC5/	7 activa	tion
Manuscript	number (if known):	HBSN-	22- 476-	R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>2023-01-0</u>	
Your Name:	Meng-jun Hou
Manuscript Title: <u>C</u> h	oline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediated
<u>autophagy via cholin</u>	e transporter SLC5A7 activation
Manuscript number (if known):HBSN-22- 476-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: 2023-01-09
Date:2023-01-09_ Your Name:Xiao_lin_Luo
Manuscript Title: <u>Choline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediatec</u>
autophagy via choline transporter SLC5A7 activation
Manuscript number (if known):HBSN-22- 476-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Dourmont or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus, manuscript writing or educational events	
6	Payment for expert	None
•	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
8	Patents planned, issued or	None
_	pending	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role	None
	in other board, society,	
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
42		
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None
13	Other financial or non-	None
15	financial interests	

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>2023-01-09</u>
Your Name:
Manuscript Title: <u>Choline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediated</u>
autophagy via choline transporter SLC5A7 activation
Manuscript number (if known):HBSN-22- 476-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Doumant or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
Ũ	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	None
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
15		
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Services Other financial or non-	Nana
13	financial interests	None

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date: <u>2023-01-09</u>			
Your Name: 5	han		
Manuscript Title: <u>Choline supp</u>	resses hepatocellular carcino	ma progression by attenuating	AMPK/mTOR-mediated
autophagy via choline transport	er SLC5A7 activation		
Manuscript number (if known):	HBSN-22- 476-R1		

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Doumant or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
Ũ	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	None
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
15		
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Services Other financial or non-	Nana
13	financial interests	None

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement:

Date:2023-01-09
Your Name:
Manuscript Title: <u>Choline suppresses hepatocellular carcinoma progression by attenuating AMPK/mTOR-mediated</u>
autophagy via choline transporter SLC5A7 activation
Manuscript number (if known):HBSN-22- 476-R1

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	None	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	None	

4	Consulting fees	None
4		None
5	Doumant or honoraria for	Nene
Э	Payment or honoraria for lectures, presentations,	None
	speakers bureaus,	
	manuscript writing or	
	educational events	
6	Payment for expert	None
Ū	testimony	
	,	
7	Support for attending	None
	meetings and/or travel	
	_	
8	Patents planned, issued or	None
Ũ	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role in other board, society,	None
	committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
15		
12	Receipt of equipment,	None
	materials, drugs, medical	
	writing, gifts or other services	
13	Services Other financial or non-	Nana
13	financial interests	None

No conflict of interest to declare.

Please place an "X" next to the following statement to indicate your agreement: